Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Androgens and prostate disease.

Cooper LA, Page ST.

Asian J Androl. 2014 Mar-Apr;16(2):248-55. doi: 10.4103/1008-682X.122361. Review.

2.

Prostate cancer risk in testosterone-treated men.

Raynaud JP.

J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):261-6. Review.

PMID:
17113983
3.

Prevention of prostate cancer by androgens: experimental paradox or clinical reality.

Algarté-Génin M, Cussenot O, Costa P.

Eur Urol. 2004 Sep;46(3):285-94; discussion 294-5. Review.

PMID:
15306098
4.

Prostate diseases--role of sex steroids and their inhibitors.

Welén K, Damber JE.

Best Pract Res Clin Endocrinol Metab. 2011 Apr;25(2):355-67. doi: 10.1016/j.beem.2010.09.008.

PMID:
21397203
5.

Testosterone and prostate cancer: revisiting old paradigms.

Isbarn H, Pinthus JH, Marks LS, Montorsi F, Morales A, Morgentaler A, Schulman C.

Eur Urol. 2009 Jul;56(1):48-56. doi: 10.1016/j.eururo.2009.03.088. Review.

PMID:
19375844
6.

Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.

Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, Bremner WJ, Gleave ME, Nelson PS.

Cancer Res. 2007 May 15;67(10):5033-41.

7.

Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase.

Wright AS, Douglas RC, Thomas LN, Lazier CB, Rittmaster RS.

Endocrinology. 1999 Oct;140(10):4509-15.

PMID:
10499505
8.

Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer.

Kasper S, Sheppard PC, Yan Y, Pettigrew N, Borowsky AD, Prins GS, Dodd JG, Duckworth ML, Matusik RJ.

Lab Invest. 1998 Jun;78(6):i-xv.

PMID:
9645768
9.

Androgen replacement therapy and prostate safety.

Morales A.

Eur Urol. 2002 Feb;41(2):113-20. Review.

PMID:
12074396
10.

Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.

Joseph IB, Nelson JB, Denmeade SR, Isaacs JT.

Clin Cancer Res. 1997 Dec;3(12 Pt 1):2507-11.

11.

Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer.

Kasper S, Sheppard PC, Yan Y, Pettigrew N, Borowsky AD, Prins GS, Dodd JG, Duckworth ML, Matusik RJ.

Lab Invest. 1998 Mar;78(3):319-33. Corrected and republished in: Lab Invest. 1998 Jun;78(6):i-xv.

PMID:
9520945
12.

Persistent intraprostatic androgen concentrations after medical castration in healthy men.

Page ST, Lin DW, Mostaghel EA, Hess DL, True LD, Amory JK, Nelson PS, Matsumoto AM, Bremner WJ.

J Clin Endocrinol Metab. 2006 Oct;91(10):3850-6.

PMID:
16882745
13.

The biology of hormone refractory prostate cancer. Why does it develop?

Isaacs JT.

Urol Clin North Am. 1999 May;26(2):263-73. Review.

PMID:
10361549
14.

A new era of testosterone and prostate cancer: from physiology to clinical implications.

Khera M, Crawford D, Morales A, Salonia A, Morgentaler A.

Eur Urol. 2014 Jan;65(1):115-23. doi: 10.1016/j.eururo.2013.08.015. Review.

PMID:
24011426
15.

Impact of male hormonal contraception on prostate androgens and androgen action in healthy men: a randomized, controlled trial.

Mostaghel EA, Lin DW, Amory JK, Wright JL, Marck BT, Nelson PS, Matsumoto AM, Bremner WJ, Page ST.

J Clin Endocrinol Metab. 2012 Aug;97(8):2809-17. doi: 10.1210/jc.2012-1536.

16.

Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.

Page ST, Hirano L, Gilchriest J, Dighe M, Amory JK, Marck BT, Matsumoto AM.

J Urol. 2011 Jul;186(1):191-7. doi: 10.1016/j.juro.2011.03.026.

17.

Preventing diseases of the prostate in the elderly using hormones and nutriceuticals.

Comhaire F, Mahmoud A.

Aging Male. 2004 Jun;7(2):155-69. Review.

PMID:
15672940
18.

Effects of androgen deficiency and replacement on prostate zonal volumes.

Jin B, Conway AJ, Handelsman DJ.

Clin Endocrinol (Oxf). 2001 Apr;54(4):437-45.

PMID:
11318778
19.

Endocrine therapy: where do we stand and where are we going?

Schröder FH.

Cancer Surv. 1991;11:177-94. Review.

PMID:
1841751
20.

Developments in the control of testicular function.

Swerdloff RS, Wang C, Bhasin S.

Baillieres Clin Endocrinol Metab. 1992 Apr;6(2):451-83. Review.

PMID:
1377467

Supplemental Content

Support Center